Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has become the reference imaging modality across the natural history of prostate cancer (PC) [1], while PSMA-targeted radioligand therapy (RLT) is now an established treatment option in the post-taxane castration-resistant setting, with encouraging data in earlier disease phases also emerging. Despite this success, PSMA is not without limitations. Nonspecific bone uptake can complicate image interpretation and [2] requires careful clinical interpretation.
European Urology published a clinical update in Research Highlights on 20 Jan 2026.
The item focuses on Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics.
Review the original article for the full source wording and details.